KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) Gross Margin (2016 - 2025)

Historic Gross Margin for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to 91.8%.

  • Regeneron Pharmaceuticals' Gross Margin rose 4200.0% to 91.8% in Q4 2025 from the same period last year, while for Dec 2025 it was 92.05%, marking a year-over-year decrease of 3000.0%. This contributed to the annual value of 92.05% for FY2025, which is 3000.0% down from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Gross Margin of 91.8% as of Q4 2025, which was up 4200.0% from 92.52% recorded in Q3 2025.
  • Regeneron Pharmaceuticals' Gross Margin's 5-year high stood at 94.78% during Q2 2022, with a 5-year trough of 314.6% in Q1 2022.
  • Moreover, its 5-year median value for Gross Margin was 92.49% (2023), whereas its average is 58.19%.
  • In the last 5 years, Regeneron Pharmaceuticals' Gross Margin tumbled by -4073600bps in 2022 and then skyrocketed by 4067200bps in 2023.
  • Quarter analysis of 5 years shows Regeneron Pharmaceuticals' Gross Margin stood at 83.61% in 2021, then crashed by -313bps to 178.0% in 2022, then skyrocketed by 152bps to 92.47% in 2023, then fell by -1bps to 91.38% in 2024, then rose by 0bps to 91.8% in 2025.
  • Its Gross Margin stands at 91.8% for Q4 2025, versus 92.52% for Q3 2025 and 92.5% for Q2 2025.